Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Omalizumab biosimilar by Curateq Biologics for Allergic Asthma: Likelihood of Approval
Omalizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Allergic Asthma. According to GlobalData,...
Omalizumab biosimilar by Curateq Biologics for Nasal Polyps (Nasal Polyposis): Likelihood of Approval
Omalizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Nasal Polyps (Nasal Polyposis). According...
Pegfilgrastim biosimilar by Curateq Biologics for Chemotherapy Induced Neutropenia: Likelihood of Approval
Pegfilgrastim biosimilar is under clinical development by Curateq Biologics and currently in Phase II for Chemotherapy Induced Neutropenia. According to...
Bevacizumab biosimilar by Curateq Biologics for Peritoneal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Peritoneal Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Metastatic Colorectal Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Metastatic Colorectal Cancer. According to...
Bevacizumab biosimilar by Curateq Biologics for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Kidney Cancer (Renal Cell Cancer)....
Bevacizumab biosimilar by Curateq Biologics for Glioblastoma Multiforme (GBM): Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Glioblastoma Multiforme (GBM). According to...
Bevacizumab biosimilar by Curateq Biologics for Cervical Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Cervical Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Ovarian Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Ovarian Cancer. According to GlobalData,...
Bevacizumab biosimilar by Curateq Biologics for Breast Cancer: Likelihood of Approval
Bevacizumab biosimilar is under clinical development by Curateq Biologics and currently in Phase I for Breast Cancer. According to GlobalData,...